|
Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment
Hasan Tahsin Gozdas, Oguz Karabay
Department of Infectious Diseases and Clinical Microbiology, Sakarya University Faculty of Medicine, Sakarya, Turkey
Correspondence Address:
Dr. Hasan Tahsin Gozdas
Department of Infectious Diseases and Clinical Microbiology, Sakarya University Faculty of Medicine, Sakarya
Turkey
Peginterferon alpha-2a (PEG IFN α-2a) is frequently used in chronic hepatitis B (CHB)treatment. Numerous adverse events can be noted during this therapy such as flu-like disease, rash, weight loss and depression. However, PEG IFN α-2a related ototoxicity seems to be an uncommon entity. Ototoxicity can be detected objectively by audiometry. In this paper, we present a case of CHB who developed reversible bilateral ototoxicity during PEG IFN α-2a treatment. Due to ototoxicity detected objectively by audiogram, treatment was ceased at sixth month and ototoxicity completely recovered one month after stopping the drug.
How to cite this article:
Gozdas HT, Karabay O. Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment.Indian J Pharmacol 2015;47:121-122
|
How to cite this URL:
Gozdas HT, Karabay O. Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment. Indian J Pharmacol [serial online] 2015 [cited 2023 Jun 3 ];47:121-122
Available from: https://www.ijp-online.com/article.asp?issn=0253-7613;year=2015;volume=47;issue=1;spage=121;epage=122;aulast=Gozdas;type=0 |
|
